Background: Extrapleural pneumonectomy (EPP) is a complex surgical procedure involving en-bloc resection of the parietal and visceral pleura, lung, pericardium, and ipsilateral diaphragm. Small case series of pleural-based sarcoma of predominantly paediatric patients suggest EPP may be a life-prolonging surgical option. We aimed to describe the characteristics and outcomes of adults who underwent EPP at a specialized sarcoma center. Methods: Clinicopathologic variables, surgical details and follow-up information were extracted for eight patients undergoing EPP for pleural-based sarcoma between 2017-2020. Primary outcomes were event-free survival (EFS) and overall survival (OS) from the date of EPP. Secondary outcomes were disease-free interval (DFI) prior to EPP, and early and late postoperative complications. Results: At median follow-up of 22.5 months, median EFS was 6.0 months and OS was 20.7 months. Six patients had disease recurrence; five patients died of progressive disease. Two patients had not recurred: one died of a radiation-related esophageal rupture, and one was alive with no evidence of disease at 37.0 months. Characteristics of those with the longest EFS included low-grade histology and achieving a metabolic response to preoperative chemotherapy. Early postoperative complications included one ventilator-associated pneumonia with new-onset atrial fibrillation and two cases of hydropneumothorax. Late surgical complications included a case of infective endocarditis and septic shock. Conclusions: In adult sarcoma patients, EPP is rarely curative but appears to be a feasible salvage procedure when performed at specialized centers. Patient selection is critical, with a strong consideration for multimodal treatment to optimize oncological outcomes.

Glioblastoma (GBM) is a malignant brain tumor that frequently occurs alongside other central nervous systems (CNS) conditions. Glutamate release and aberrant cellular behavior are shared features of both CNS diseases and GBM cells. Neither their origin nor the ways in which CNS disorders affect the development or behavior of GBM are well understood. Using data from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) datasets–where both healthy and cancerous samples were analyzed–we used a quantitative analytical framework to identify differentially expressed genes (DEGs) and cell signaling pathways that might be related to GBM. Then, we performed gene ontology studies and hub protein identifications to estimate the roles of these DEGs after finding disease-gene connection networks and signaling pathways. Using the GEPIA Proportional Hazard Model and the Kaplan-Meier estimator, we widened our analysis to identify the important genes that may play a role in both progression and the survival of patients with GBM. Totally, 890 DEGs, including 475 and 415 up- and down-regulated were identified, respectively. Our results revealed SQLE, DHCR7, delta-1 phospholipase C ( PLCD1), and MINPP1 genes are high expression, and the Enolase 2 ( ENO2) and hexokinase-1 ( HK1) genes are low expressions. Hence, our findings suggest novel mechanisms that affect the occurrence of GBM development, growth, and/or establishment and may also serve as secretory biomarkers for GBM prognosis and possible targets for therapy.

Background: Nanomedicine, or Phyto nanomedicine, has emerged as a promising solution to enhance therapeutic efficacy by altering the pharmacokinetics and pharmacodynamics of the phytochemicals. Nanomedicines have been developed for enhancing the therapeutic efficacy of the treatments of various diseases. Cancer is the second leading cause of mortality worldwide. Recent findings: Currently available anticancer therapeutic strategies are not sufficient to improve the survival rate of patients. Even significant promising development over the past few decades have not been observed. Recent studies evidenced that cancer cells develop multidrug resistance (MDR) against chemotherapeutics and this leads to enhanced proliferation, invasion and metastasis. Hence, there is an urgent need for an alternative strategy to treat this silent killer. Recently, phytochemicals have gained immense attention as a promising anticancer agent by targeting multimodal oncogenic pathways, inducing cell cycle arrest and apoptosis in preclinical studies. Conclusion: Being multi pathway target oriented Phytochemicals if clubbed with Nanotechnology can prove to be better tool for combating this deadly disease. Therefore, to address these challenges, phytochemical-based nanomedicines (phytonanomedicine) have been developed that not only improve pharmacokinetics profile of drugs but also provide a less toxic multitargeted treatment regimen. In this review, we summarize the current status of nano phytomedicine as anticancer drugs, focusing on the role of phytomedicine in translational cancer research.